345 related articles for article (PubMed ID: 22817713)
1. Tau oligomers and tau toxicity in neurodegenerative disease.
Ward SM; Himmelstein DS; Lancia JK; Binder LI
Biochem Soc Trans; 2012 Aug; 40(4):667-71. PubMed ID: 22817713
[TBL] [Abstract][Full Text] [Related]
2. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
Combs B; Hamel C; Kanaan NM
Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.
Kanaan NM; Morfini GA; LaPointe NE; Pigino GF; Patterson KR; Song Y; Andreadis A; Fu Y; Brady ST; Binder LI
J Neurosci; 2011 Jul; 31(27):9858-68. PubMed ID: 21734277
[TBL] [Abstract][Full Text] [Related]
4. Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.
Tiernan CT; Combs B; Cox K; Morfini G; Brady ST; Counts SE; Kanaan NM
Exp Neurol; 2016 Sep; 283(Pt A):318-29. PubMed ID: 27373205
[TBL] [Abstract][Full Text] [Related]
5. TOC1: characterization of a selective oligomeric tau antibody.
Ward SM; Himmelstein DS; Lancia JK; Fu Y; Patterson KR; Binder LI
J Alzheimers Dis; 2013; 37(3):593-602. PubMed ID: 23979027
[TBL] [Abstract][Full Text] [Related]
6. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.
Patterson KR; Remmers C; Fu Y; Brooker S; Kanaan NM; Vana L; Ward S; Reyes JF; Philibert K; Glucksman MJ; Binder LI
J Biol Chem; 2011 Jul; 286(26):23063-76. PubMed ID: 21550980
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport.
Kanaan NM; Morfini G; Pigino G; LaPointe NE; Andreadis A; Song Y; Leitman E; Binder LI; Brady ST
Neurobiol Aging; 2012 Apr; 33(4):826.e15-30. PubMed ID: 21794954
[TBL] [Abstract][Full Text] [Related]
8. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
9. Tau Oligomers.
Maeda S; Takashima A
Adv Exp Med Biol; 2019; 1184():373-380. PubMed ID: 32096050
[TBL] [Abstract][Full Text] [Related]
10. Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis.
Penke B; Szűcs M; Bogár F
Molecules; 2020 Apr; 25(7):. PubMed ID: 32260279
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport.
Patterson KR; Ward SM; Combs B; Voss K; Kanaan NM; Morfini G; Brady ST; Gamblin TC; Binder LI
Biochemistry; 2011 Nov; 50(47):10300-10. PubMed ID: 22039833
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.
Abskharon R; Seidler PM; Sawaya MR; Cascio D; Yang TP; Philipp S; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Felgner PL; Nakajima R; Glabe CG; Eisenberg DS
J Biol Chem; 2020 Jul; 295(31):10662-10676. PubMed ID: 32493775
[TBL] [Abstract][Full Text] [Related]
13. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
14. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
15. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
16. Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates.
Islam T; Kvartsberg H; Sehrawat A; Kac PR; Becker B; Olsson M; Abrahamson EE; Zetterberg H; Ikonomovic MD; Blennow K; Karikari TK
Alzheimers Dement; 2024 Apr; 20(4):2894-2905. PubMed ID: 38520322
[TBL] [Abstract][Full Text] [Related]
17. Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease.
Mufson EJ; Ward S; Binder L
Neurodegener Dis; 2014; 13(2-3):151-3. PubMed ID: 24029627
[TBL] [Abstract][Full Text] [Related]
18. Purification and Characterization of Low-n Tau Oligomers.
Kaniyappan S; Chandupatla RR; Mandelkow E
Methods Mol Biol; 2018; 1779():99-111. PubMed ID: 29886530
[TBL] [Abstract][Full Text] [Related]
19. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease.
Lee S; Choi BR; Kim J; LaFerla FM; Park JHY; Han JS; Lee KW; Kim J
Mol Nutr Food Res; 2018 Jun; 62(12):e1800240. PubMed ID: 29714053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
